Immune responses to components of hepatitis B virus (HBV) are assumed to play an essential role not only in the elimination of the virus but also in the pathogenesis of HBV-induced hepatitis. Protective humoral immunity to HBV is mediated by immune responses to HBV surface antigen (HBsAg). It is important to know which HBsAg preparations induce which type of cellular and humoral immune responses under which immunization conditions. We studied in BALB/c mice the humoral (antibody) response and the class I-restricted cytotoxic T-lymphocyte (CTL) response to different preparations of HBsAg particles: recombinant, small protein particles; plasma-derived, mixed particles formed by large, medium, and small surface proteins; and different preparations of recombinant, mixed particles formed by large and small surface proteins. Specific antibody levels appeared in the sera of immunized mice 2 to 3 weeks after immunization and were correlated with the antigen dose used for priming. HBsAg-specific antibody levels were enhanced by boost injections or by adsorbing the antigen to aluminum hydroxide. Injected in particulate form without adjuvants in the dose range of 0.1 to 10 ,ug per mouse, all HBsAg preparations tested efficiently primed specific CD8+ CTL of defined restriction and epitope specificity. Specific CTL reactivity was detectable from 5 days to more than 4 months postimmunization. In the dose range tested, it was independent of the antigen dose used for immunization and not enhanced by repeated boost injections. CTL were not elicited by HBsAg adsorbed to aluminum hydroxide. We have thus defined conditions under which HBsAg induced preferentially either a cellular immune response or a humoral immune response. These findings may be relevant for the interpretation of HBV-associated immunopathologic phenomena.
Hepatitis B virus (HBV) surface antigens (HBsAg) are immunodominant antigens. The recombinant HBV small surface (S) protein adsorbed to aluminum hydroxide (alum) is the only recombinant vaccine now in widespread use to treat humans (8, 9) . This vaccine has proven its effectiveness beyond doubt. Protection against HBV induced by this vaccine is correlated with high levels of serum antibodies specific for HBsAg (8, 9) . It is unknown whether anti-HBsAg-specific, major histocompatibility complex (MHC) class I-restricted CD8+ cytotoxic T lymphocytes (CTL) are induced by this type of vaccination and whether anti-HBsAg-specific CTL are involved in the protective immune response against HBV. In HBsAg carriers persistently infected with HBV, anti-HBsAgspecific antibody levels are undetectable, and high levels of HBsAg particles are present in serum. Anti-HBsAg-specific CD8+ CTL have been isolated from some of these patients (17) . It has been hypothesized that CD8+ CTL contribute to the immunopathology associated with acute or chronic HBV infection. CTL may destroy large numbers of HBV-infected hepatocytes (1, 25) . Furthermore, CTL may specifically eliminate anti-HBsAg-specific B cells and hence reduce antiHBsAg-specific B cells and hence reduce anti-HBsAg-specific antibody levels (2, 3, 10) . It HBsAg preparations. Recombinant S-protein particles have the unusual property that they efficiently prime a specific CTL response after a single injection of 0.1 to 10 ,ug of the antigen given without adjuvants. We show in the experimental system described that a small recombinant, viral protein of potential interest for human protective immunity and disease (HBVinduced hepatitis) can specifically stimulate in soluble form a CD8+ CTL response. Unexpectedly, a single immunization of mice with the same dose of S antigen adsorbed to alum elicited substantial antibody titers but failed to stimulate a CTL response. Different modes of immunization with HBsAg can thus stimulate preferentially either a humoral or a cellular immune response.
MATERIALS AND METHODS
Mice. BALB/cJ mice (H-2d Ld+) and BALB/c H-2d"2 (H_2d Ld -) (dm2) mice were bred under specific-pathogen-free conditions in the animal colony of the Institute of Microbiology, Ulm University, Ulm, Germany. Male and female mice were used at 12 to 16 weeks of age.
Cells. The H-2d mastocytoma cell line P815 (TIB 64) and the H-2d B-lymphoma cell line A20 (TIB 208) were obtained from the American Type Culture Collection (Rockville, Md.).
Recombinant S antigen. The S-protein (HBsAg) sequence, subtype ad, was inserted into the Hansenula polymorpha expression vector pMPT121 and transformed into H. polymorpha host strain RB10 (12) . Yeast transformants efficiently expressing S protein were established as strains for fermentation. Yeast cells were disrupted in a large-scale commercial bead mill, and the crude extract was cleared by centrifugation. S-antigen particles were purified by adsorption to silica gel, column chromatography, and isopycnic ultracentrifugation as described previously (12, 16) . Analysis of the purified S antigen by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and Western blotting (immunoblotting) by using polyclonal rabbit anti-S-antigen antibodies (lot no. 61WN003; Behringwerke, Marburg, Germany) and 35S-labeled protein A as described previously (32) revealed a homogeneous band with an apparent molecular mass of 24 kDa expected for the nonglycosylated form of the S antigen (Fig.  1A) . Preparations of recombinant S-protein particles extensively dialyzed to remove peptides revealed no evidence of contaminating S-protein monomers, dimers, or proteolytic fragments (Fig. 1A) . The S protein used for immunization self-assembled into typical 20-nm particles, as demonstrated in electron microscopic examinations of the antigen preparation (Fig. 1A) .
Recombinant mixed S/L particles, composed of S and large (L) HBV surface proteins (at a ratio of 1:15), were produced in H. polymorpha as described previously (16 Peptides were synthesized in a model 431A Applied Biosystems peptide synthesizer and purified by reverse-phase highpressure liquid chromatography. Peptides were dissolved in a 70% acetonitrile-0.1% trifluoroacetic acid stock solution at a concentration of 10 mg/ml and diluted with culture medium for use. In the described experiments, we used the synthetic 12-mer peptide IPQSLDSWWTSL (S28-39) and the synthetic 15-mer peptide ILTIPQSLDSWWTSL (S25-39), which represent a defined Ld-restricted CTL epitope of the S protein in H-2d BALB/c mice (1, 25) .
In vitro restimulation of CTL and cytotoxicity assay. Singlecell suspensions were aseptically prepared from spleens of immunized mice 6 days after the antigen injection. Cells were suspended in o-MEM (GIBCO, Berlin, Germany) supplemented with 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) buffer, 5 x 10-5 M 2-mercaptoethanol, antibiotics, and 10% (vol/vol) fetal calf serum (Pan Systems, Aidenbach, Germany). To the culture medium was further added 5% (vol/vol) of a selected batch of concanavalin A-stimulated rat spleen cell supernatant containing interleukin-2 (29) . Responder cells (3 x 107) were cocultured with 1.5 x 106 syngeneic, S-antigen-expressing transfectants (irradiated with 20,000 rad) in 10 ml of medium in upright 25- Determination of serum antibody levels. Antibodies against the HBV S antigen were detected in mouse sera by using the commercially available test IMxAUSAB (Abbott, Wiesbaden, Germany). In this readout, microparticles coated with HBsAg were mixed with mouse serum samples to allow specific binding of anti-S-antigen antibodies. Microparticles coated with antigen-antibody complexes were transferred and irreversibly bound to a glass fiber matrix. Biotinylated recombinant S antigen was added, and binding to the complex was traced by an alkaline phosphatase-conjugated antibiotin antibody followed by the addition of the substrate 4-methylumbelliferyl phosphate. Antibody levels were quantified by using six standard sera (0 to 1,000 mIU/ml). The tested sera were diluted so that the measured optical density values were between those of standard sera 1 (Fig. 2C) . Anti-S-antigen-specific CTL responses were not observed in primary MLTC, in which lymph node or spleen responder cells from unprimed BALB/c mice were cocultured with A20/S or P815/S transfectants in the presence of conditioned medium ( Fig. 2A) . In vivo priming of CTL was thus essential for the induction of a specific cytolytic response. Methods of priming of mice with S particles by the subcutaneous, intraperitoneal, and intravenous routes were equally efficient (data not shown). Comparable levels of specific CTL reactivity were found in mice immunized with 100 ng, 1 pLg, or 10 ,ug of the antigen (Table 1) . A boost injection with S-antigen particles was not required to reveal this response (Table 1 ). Effector cells of this response expressed the CD3+ CD4-CD8+ phenotype because they were eliminated by treatment with anti-CD8 antibody plus complement but were not affected by treatment with anti-CD4 antibody plus complement (Table 2) . BALB/c-derived CTL lysed S-antigen-expressing H-2d MHC class I' class II-P815/S targets and class I' class I1I A20 targets equally well ( Fig. 2B and D ). An anti-Ld_specific monoclonal antibody blocked lysis of P815/S targets by primed CTL (data not shown). Immunization of H-2d Ld+ BALB/c but not the congenic H-2d Ld -BALB/c dm2 mice stimulated an S-specific CTL response (Table 3 ). These data indicate that all S-antigenspecific CD8+ CTL from BALB/c mice are Ld restricted (1, 25) . CTL primed by S-protein particles recognized an epitope located between residues 28 and 39 of the S protein ( Fig. 2B  and D CTL are primed by different preparations of naked Santigen particles. A specific CTL response of BALB/c mice to S antigen was induced with comparable efficiency with S particles, with S/L particles, or with S/AL particles (Table 1) . Plasma-derived S particles composed of S, M, and L surface proteins were also very efficient in eliciting a CTL response in BALB/c mice (data not shown). The S-specific CTL reactivity was detectable for at least 3 months after the antigen injection. Boost injections with the same dose of the antigen used for priming (administered 3 to 15 weeks after the first injection) did not enhance the specific CIL reactivity (Table 1) . We excluded the possibility that the partial proteolytic degradation of S protein after its injection into the mouse yielded extracel- The specific antibody response of BALB/c mice to recombinant S-particles. Three weeks postinjection, the levels of antibody specific for S antigen in the sera of immunized mice were determined (Fig. 3) . Animals BALB/c mice were immunized intraperitoneally with different S-antigen preparations, using the doses (micrograms per injection) indicated in parentheses. Specific antibody levels were measured in the sera of immunized mice 3 weeks after the priming injection and 3 weeks after a boost injection. The same dose of antigen was used for the priming injection and for the boost injection. Mice were immunized with S antigen either in the form of naked particles (bottom eight groups) or adsorbed to alum (upper eight groups). The antigen preparations tested were recombinant, yeast-expressed S particles, S/L particles, and purified human plasma-derived HBsAg (pHBsAg). The values for three individual mice in each group are shown. nized with S antigen plus adjuvants, the specific anti-S antibody levels in serum were 10-to 103-fold higher in primary and in boosted responses compared with serum antibody levels detectable in mice immunized with S-antigen without adjuvants (Fig. 3) .
Comparison of primary and boosted responses of CD8+ CTL and B cells of BALB/c mice with responses to HBV S antigen administered with or without adjuvants. The CD8+ CTL reactivity of BALB/c mice to soluble S-protein particles was detectable as early as 5 days after the immunization and persisted for many months. It was independent of the antigen dose used for immunization in the range of 0.1 to 10 jig of antigen per mouse and was not enhanced by repeated boost injections. It was not elicited when mice were immunized with S particles adsorbed to alum or emulsified in mineral oil (Fig.  4) .
The humoral (B-cell) response of BALB/c mice to S protein measured in terms of specific antibody levels in serum appeared 2 to 3 weeks after immunization. It was correlated with the antigen dose used for priming and was enhanced by boost injections and by immunizing mice with S particles adsorbed to alum or emulsified in mineral oil (Fig. 4) . The CTL response induced by recombinant S-protein particles. This report, describes a novel aspect of the immunogenicity of the HBV S antigen for T cells: naked S-antigen particles injected by different routes (subcutaneously, intravenously, and intraperitoneally) into BALB/c mice efficiently primed anti-S-antigen-specific CD8+ CTL. It is not known why naked S-antigen particles are so efficient in priming CTL in vivo. The general rule seems to be that soluble protein antigens enter antigen-presenting cells (APC) by endocytosis, are processed via the exogenous pathway in a late endosomal compartment, are presented on the surface of APC in the context of MHC class II glycoproteins, and selectively stimulate CD4+ T cells (reviewed in references 4 and 21). In contrast, CD8+ CTL usually recognize peptides derived from intracellularly synthesized and processed endogenous protein antigens that are presented on the cell surface in association with MHC class I molecules (reviewed in references 13, 35, and 40) . Some exceptions to this rule have been published recently. We reported that the injection of recombinant large T antigen of the simian virus 40 into C57BL/6 (H-2") mice efficiently primed CD8+ CTL in vivo (31, 32) . Intraperitoneal, subcutaneous, or intramuscular injection into BALB/c mice of a single dose of 10 ,ug of purified, soluble influenza virus nucleoprotein (NP) without adjuvants stimulated anti-NP-specific CTL responses (33, 37) . Influenza virus hemagglutinin-specific CD8+ CTL were induced by soluble, recombinant protein produced in Escherichia coli (39) . The poliovirus VPI capsid protein apparently entered the endogenous processing pathway in vivo and in vitro after immunization of BALB/c mice with 20 jig of the soluble form of this structural viral protein (20) . Some covalent modifications of protein antigens such as lipid conjugation facilitate their access to the endogenous processing pathway and their stimulation of a CD8+ CTL response in vivo (7, 24, 30 (20) . Adjuvants have been extensively used to augment immune responses to antigen. They will be increasingly important to realize the promises of recombinant proteins and peptides for use as synthetic subunit vaccines. Alum is the only adjuvant currently authorized for human use. The data reported in this paper stress the importance of defining the role of adjuvants in favoring sensitization of certain selected lymphocyte subsets at the expense of others. In addition to augmenting B-cell responses, many adjuvants seem to change the pattern of Tand/or B-cell subsets stimulated in response to antigen. It has become obvious in many experimental models that different T-cell subsets play distinct disease-preventing or disease-promoting roles during a particular infection. An essential prerequisite for vaccine development is to find an appropriate way to deliver the antigen so that it will stimulate the right type of protective response and will avoid the induction of undesirable or even dangerous immunopathological reactions.
DISCUSSION
The anti-HBsAg immune reactivity in HBV-induced liver pathology. For many years, effective methods for the virological diagnosis of HBV infections have been established, and the diagnostic value of markers that correlate with the course of HBV infection and HBV-induced disease has been established (reviewed in reference 15). In contrast, very little is known about the factors that determine the very different clinical course of HBV infection in patients. Three different courses of the disease are observed in HBV-infected adults. (i) About 25% of HBV-infected adults will suffer from acute hepatitis. Of these, about 1% will die from fulminant hepatitis with liver dystrophy, and 99% will recover with production of anti-HBsAg antibodies and lifelong immunity. (ii) About 65% 
